Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Placebo to BIBR 1048 MS; Drug: BIBR 1048 MS dose 1; Drug: BIBR 1048 MS dose 2; Drug: BIBR 1048 MS dose 3; Drug: BIBR 1048 MS dose 4; Drug: BIBR 1048 MS dose 5

• Registration Number: NCT02170116
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

The objective of this study was to assess safety, pharmacokinetics and the effect of BIBR 953 ZW on coagulation parameters of BIBR 953 ZW after oral single doses of the prodrug, BIBR 1048 MS, in healthy male subjects. This was the first administration of this substance to humans.

Detailed Description

Not available

Study Timeline

• Study Start: 1998-11
• Primary Completion: 1998-12
• Status Verified: 2014-06
• Study First Submitted: 2014-06-20
• Study First Submitted QC: 2014-06-20
• Last Update Submitted: 2014-06-20
• Study First Posted: 2014-06-23
• Last Update Posted: 2014-06-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

• Healthy male subjects as determined by results of screening
• Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
• Age >= 18 and <= 45 years
• Broca >= - 20 % and <= + 20 %

Exclusion Criteria

• Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance

• History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders

• History of orthostatic hypotension, fainting spells or blackouts

• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders

• Chronic or relevant acute infections

• History of

  • allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • any bleeding disorder including prolonged or habitual bleeding
  • other hematologic disease
  • cerebral bleeding (e.g. after a car accident)
  • commotion cerebri

• Intake of drugs with a long half-life (> 24 hours) within 1 month prior to administration

• Use of any drugs which might influence the results of the trial within 10 days prior to administration or during the trial

• Participation in another trial with an investigational drug within 2 months prior to administration or during trial

• Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days

• Alcohol abuse (> 60 g/day)

• Drug abuse

• Blood donation within 1 month prior to administration or during the trial

• Excessive physical activities within 5 days prior to administration or during the trial

• Any laboratory value outside the clinically accepted reference range

• History of any familial bleeding disorder

• Thrombocytes < 150000/µl

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo to BIBR 1048 MS	-
BIBR 1048 MS dose 1	BIBR 1048 MS dose 1	-
BIBR 1048 MS dose 2	BIBR 1048 MS dose 2	-
BIBR 1048 MS dose 3	BIBR 1048 MS dose 3	-
BIBR 1048 MS dose 4	BIBR 1048 MS dose 4	-
BIBR 1048 MS dose 5	BIBR 1048 MS dose 5	-

Primary Outcome Measures

Name	Time	Method
Changes from baseline in prothrombin time (PT) (International Normalised Ratio (INR))	- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours after administration
Changes from baseline in activated partial thromboplastin time (aPTT)	- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours after administration

Secondary Outcome Measures

Name	Time	Method
Changes from baseline in Ecarin Clotting Time (ECT)	up to day 3
Changes from baseline in Pulse rate	up to day 3
Peak (maximum) plasma concentration (Cmax) of BIBR 953 ZW	- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration
time to reach the peak plasma concentration (tmax ) of BIBR 953 ZW	- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration
AUC0-12 h - Area under the plasma concentration-time curve of BIBR 953 ZW from 0 to 12 h	- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration
Area under the plasma concentration-time curve (AUC0-infinity) of BIBR 953 ZW from 0 to infinity	- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration
Area under the plasma concentration-time curve of BIBR 953 ZW (AUCtf -infinity) from tf (last time point when measured plasma concentration) to infinity expressed as % of AUC0-infinity	- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration
Terminal half-life(t1/2 ) of BIBR 953 ZW derived from non-compartmental analysis	- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration
Total mean residence time (MRTtot ) of BIBR 953 ZW	- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration
Total clearance (CLtot /f ) of BIBR 953 ZW after oral administration	24 hours after administration
Volume of distribution (Vz/f ) of BIBR 953 ZW during terminal phase after oral administration	- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration
Changes from baseline in Systolic and diastolic blood pressure	up to day 3
Occurrence of Adverse events	up to day 3
Changes from baseline in thrombin time	up to day 3
Changes from baseline in thrombin inhibition test time	up to day 3